Challenges and advances of immune checkpoint therapy
Clinical and Translational Discovery · 2024-12 · 4 (6)
DOI: 10.1002/ctd2.70001 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Translational Discovery, online erschienen am 04.11.2024. Verfasst von Lingyu Li und 1 weiteren Autor:innen. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 215 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Background and Objectives Immuno‐checkpoint therapy (ICT) significantly alters the clinical course of cancer patients, providing long‐lasting clinical benefits and offering the potential for cure to some patients. However, response rates for different tumour types vary, and predictive biomarkers are needed to enhance patient selection for the purpose of optimising effectiveness and reducing toxicity. This has driven efforts to decipher the immune and non‐immune factors that regulate ICT response. Main Content This review offers a thorough examination of the advantages and future challenges of immune checkpoint inhibitors in cancer therapy. Additionally, we explore ongoing efforts to address current challenges, such as guiding subsequent clinical trials, developing ICT combination therapy strategies and utilising epigenetics to enhance clinical efficacy. Conclusion and Perspectives Despite significant progress, ICT faces challenges including immune‐related adverse events (irAEs) and resistance mechanisms. Ongoing research focuses on developing novel biomarkers, combination therapies, and epigenetic strategies to improve the efficacy and safety of ICT for cancer patients worldwide. Future studies are required to validate these findings across different tumor types and treatment settings.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Li, L., & Sun, Y. (2024). Challenges and advances of immune checkpoint therapy. Clinical and Translational Discovery, 4(6). https://doi.org/10.1002/ctd2.70001
Vancouver
Li L, Sun Y. Challenges and advances of immune checkpoint therapy. Clinical and Translational Discovery. 2024;4(6). doi:10.1002/ctd2.70001
BibTeX
@article{Li2024,
author = {Li, Lingyu and Sun, Yingli},
title = {Challenges and advances of immune checkpoint therapy},
journal = {Clinical and Translational Discovery},
year = {2024},
volume = {4},
number = {6},
doi = {10.1002/ctd2.70001}
}
EUVIMED